What's Happening With These Business Services Stocks? -- Euronet Worldwide, First Data, Global Payments, and Interpace Diagnostics
NEW YORK, March 9, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EEFT, FDC, GPN, and IDXG which can be accessed for free by signing up to www.wallstequities.com/registration. For today, WallStEquities.com scans Euronet Worldwide Inc. (NASDAQ: EEFT), First Data Corp. (NYSE: FDC), Global Payments Inc. (NYSE: GPN), and Interpace Diagnostics Group Inc. (NASDAQ: IDXG). These stocks belong to the Business Services space, which provides support services to businesses. Worldwide demand in the sector is driven by new business growth, job growth, increasing corporate involvement, and increasing disposable income.
All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Euronet Worldwide
On Thursday, shares in Leawood, Kansas headquartered Euronet Worldwide Inc. rose slightly by 0.41%, ending the day at $87.35. The stock recorded a trading volume of 359,263 shares. The Company's shares have advanced 0.63% in the last month and 6.05% over the past year. The stock is trading below its 50-day moving average by 1.13%. Moreover, shares of Euronet Worldwide, which provides payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers worldwide, have a Relative Strength Index (RSI) of 54.40. Get the full research report on EEFT for free by clicking below at:
www.wallstequities.com/registration/?symbol=EEFT
First Data
Shares in First Data Corp. ended the day 0.33% higher at $15.20 with a total trading volume of 5.41 million shares. The stock is trading below its 50-day moving average by 9.06%. Shares of the Company, which provides electronic commerce solutions for merchants, financial institutions, and card issuers worldwide, have an RSI of 37.58.
On February 14th, 2018, research firm Bernstein upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On March 05th, 2018, First Data announced that Frank Bisignano, Chairman and CEO, will present at the Barclays Emerging Payments Forum on March 14th, 2018, at 10:50 a.m. EDT at the InterContinental New York Times Square. A live webcast and replay of the presentation will be available under the investor relations section of the Company's website. Today's complimentary research report on FDC is accessible at:
www.wallstequities.com/registration/?symbol=FDC
Global Payments
At the close of trading on Thursday, shares in Atlanta, Georgia headquartered Global Payments Inc. finished 0.19% higher at $114.53 with a total trading volume of 565,484 shares. The stock has advanced 8.04% in the last month, 18.52% over the previous three months, and 42.68% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 6.05% and 15.85%, respectively. Additionally, shares of Global Payments, which provides payment technology and software solutions for credit cards, debit cards, electronic payments, and check-related services, have an RSI of 60.86.
On February 15th, 2018, Global Payments announced its results for Q4 and year ended December 31st, 2017. For Q4 2017, GAAP revenues were $1,054.3 million; adjusted net revenue was $939.0 million; adjusted earnings per share (EPS) were $1.07; and adjusted operating margin was 30.3%. For the full year 2017, GAAP revenues were $3.98 billion; adjusted net revenue was $3.52 billion; adjusted EPS was $4.01; and adjusted operating margin was 29.9%.
On March 02nd, 2018, research firm Piper Jaffray upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Register now for your free research document on GPN at:
www.wallstequities.com/registration/?symbol=GPN
Interpace Diagnostics Group
Parsippany, New Jersey headquartered Interpace Diagnostics Group Inc.'s shares recorded a trading volume of 701,003 shares at the end of yesterday's session, which was above their three months average volume of 606,510 shares. The stock closed the day 1.98% higher at $1.03. The Company's shares have advanced 7.38% in the past month and 1.98% in the previous three months. The stock is trading below its 50-day moving average by 0.70%. Additionally, shares of Interpace Diagnostics, which develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers, have an RSI of 53.24.
On February 22nd, 2018, research firm Laidlaw initiated a 'Buy' rating on the Company's stock, with a target price of $4.50 per share.
On February 26th, 2018, Interpace Diagnostics Group (IDXG) announced that Horizon Blue Cross Blue Shield of New Jersey, the oldest and largest health plan in New Jersey covering 3.8 million patients living in the Northeastern United States, has agreed to cover both of IDXG's molecular-based thyroid tests, ThyGenX® and ThyraMIR®, for its members, effective January 09th, 2018. Click on the link below and see our free report IDXG at:
www.wallstequities.com/registration/?symbol=IDXG
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article